Capricor Therapeutics (CAPR) Interest Expenses (2013 - 2026)

Capricor Therapeutics' Interest Expenses history runs 14 years deep, the most recent figure standing at $614675.0 for Q1 2026.

• On a quarterly basis, Interest Expenses rose 170.54% year-over-year to $614675.0 in Q1 2026; TTM through Mar 2026 was $3.4 million, a 394.59% increase from a year earlier, with the FY2025 full-year figure at $278.2 million, up 173.29% from the prior year.
• Interest Expenses declined to $614675.0 in Q1 2026 per CAPR's latest filing, from $2.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $118.5 million in Q3 2024 and bottomed at -$305840.0 in Q4 2022.
• The 5-year median for Interest Expenses is $3.7 million (2023), against an average of $17.4 million.
• Across the five-year window, Interest Expenses slumped 131.61% in 2022 and jumped 96505.09% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$305840.0 in 2022, then soared by 167.04% to $205043.0 in 2023, then gained by 10.55% to $226677.0 in 2024, then soared by 936.4% to $2.3 million in 2025, then tumbled by 73.84% to $614675.0 in 2026.
• Per Business Quant, the three latest CAPR Interest Expenses figures stand at $614675.0 (Q1 2026), $2.3 million (Q4 2025), and $33.4 million (Q3 2025).